述评

    下一步怎么办?“预后好” 的早期乳腺癌的诊断

    越多, 正确地进行辅助治疗越困难,给部分妇女带来

    过度治疗的危险。这对淋巴结阴性而激素受体阳性

    的乳腺癌尤其重要。对乳腺癌标记基因表达的特点

    更深入的理解可能带来新的分类方法, 可以既包含

    预后信息又包含预测信息11。一项试验已经在绝经

    前妇女中研究这一方法, 将微阵列标记和传统的标

    准相比较12。

    最后, 尽管此处的讨论强调乳腺癌生存的提高

    应归功于全身治疗和小的、 淋巴结阴性肿瘤的诊断,但两者都不能影响发病率。即使估计预后良好, 诊

    断乳腺癌也是非常可怕的, 一级预防才是真正的目

    的, 我们不应该忽略这一点。

    Alison L Jones consultant

    Academic Department of Oncology, Royal Free and University College

    Hospitals, London NW3 2QG ( alison. jones@ royalfree. nhs. uk)

    利益冲突( Competing interes ts) : AJ conducts clinical trials sponsored by

    a number of pharmaceutical companies and is on the advisory board of

    some companies including AstraZeneca, Novartis, Bristol Myers Squib,and Sanofi -Aventis.

    ( 樊英 译 徐兵河 校)

    参考文献

    1 Sa nt M, Allema ni C, Be rrino F , Coleman MP , Aareleid T, Chaplain G, et

    al. Brea st c ance r survival in Europe and the Uni te d Sta tes . Ca ncer 2004 ; 100:

    715-22.

    2 Sa insbury R, Johns ton C, Howard B. Effect on survival of de la ys in referr al of

    pa tients wi th brea st c ancer symptoms : a ret rospec tive analys is. La ncet 1999;

    353: 1132 -5.

    3 Olse n AH, Njor S, Ve jbor g W, et al. Bre as t ca ncer morta li ty in Copenhagen

    after intr oduct ion of mammography scr eening: cohort s tudy. BMJ 2005 ; 330:

    220-2.

    4 Bonadonna G, Mol iterni A, Zambett i M, Da idone MG, P ilot ti S, Gia nni L, et

    al. 30 ye ars′fol low up of r andomise d studie s of a djuva nt CMF in ope rable

    br eas t c ancer : cohort s tudy. BMJ 2005; 330 : 217 -20.

    5 Blanks RG, Moss SM, McGahan CE, Quinn MJ , Babb PJ . Effect of NHS

    br eas t scre ening pr ogramme on morta li ty from bre as t c ancer in England and

    Wales 1990-8: comparison of observe d wi th pr edic te d mor ta li ty. BMJ 2000;

    321: 665-9.

    6 Early Brea s t Ca ncer Trials Col la borat ive Group. P olychemothe rapy for ea rly

    br eas t c ancer : an ove rview of r andomise d t rials. La ncet 1998 ; 352: 930-42.

    7 Hebert - Croteau N, Brisson J , Lat rei lle J , R ivard M, Abdelaziz N, Ma rt in G.

    Complianc e wi th conse nsus recommendat ions for system ic therapy is as soc ia ted

    with improved survival of women with node -ne gat ive br eas t c ancer. J Clin

    Oncol 2004 ; 22: 3685-93.

    8 Howel l A, Cuzic k J , Ba um M, Buzdar A, Dowse tt M, For bes JF , et al .

    Resul ts of the ATAC ( Arimidex, Tamoxifen, alone or in c ombina tion ) t rial

    after c omplet ion of 5 year s′adjuvant t reatme nt for breas t c ancer. Lancet 2005;

    365: 60-2.

    9 Gos s PE, Ingle JN, Mart ino S, Robert NJ , Mus s HB, P icca rt MJ, et al. A

    randomised tr ial of letrozole in pos tmenopausal women after five year s of tamoxi fen

    therapy for early-s ta ge brea st ca nce r. N Engl J Med 2003; 349: 1793-802.

    10 Coombes RC, Hal l E, Gibson LJ , Pa rida ens R , Jas sem J , Delozier T, et al .

    A randomised t rial of exemes tane after two to three year s of tamoxi fe n thera py

    in pos tme nopausal women with primar y br eas t ca ncer. N Engl J Med 2004;

    350: 1081 -92.

    11 Soti riou C , Neo SY, McShane LM, Korn EL, Long PM, Jazae ri A, e t al .

    Breas t cance r clas s ificat ion and prognos is based on ge ne expr es sion pr ofiles

    from a populat ion-based s tudy. P roc Na t l Aca d Sci USA 2003; 100 : 10393-8.

    12 Van de Vijve r MJ , He YD, van′ t Veer LJ , Dai H, Ha rt AA, Voskui l DW, et

    al. A gene -expres s ion s ignature as a predictor of survival in bre as t c ancer. N

    Engl J Med 2002 ; 347: 1999-2009.

    BMJ 2005; 330 : 205-6

    评价乳腺癌筛查的新方法

    通过随机对照临床试验评估过度诊断

    Evaluating new screening tests for br east cancer

    May require randomised controlled trials to assess overdetection

    使用磁共振成像( MRI )方法对具有乳腺癌相关

    基因高突变风险的妇女进行筛查, 引起了人们对于

    新型有效的筛查方法所需具备的条件的争论 ......